6月4日，礼来盘中上涨3.16%，报1124.88美元/股，成交额9.8亿美元。
消息面上，近期礼来密集释放利好：公司拟以70亿美元收购Kelonia布局体内CAR-T领域，同时与Ascidian签署高达19亿美元的RNA编辑协议，并与海思科达成30.5亿美元药物发现合作。此外，礼来宣布将德国原定23亿欧元投资缩减五成，转投美国宾夕法尼亚州新建生产园区，优化全球产能布局。公司首席并购负责人表示，依托GLP-1减肥药充沛现金流，礼来并购扩张意愿达到历史峰值。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.